Primary cardiac angiosarcoma with thrombosis and multiple bone marrow metastases mimicking lymphoma on 18F-FDG PET/CT

Author(s):  
Maoqing Jiang ◽  
Ping Chen ◽  
Jianjun Zheng
2019 ◽  
Vol 19 (10) ◽  
pp. e35-e36
Author(s):  
Frédéric Lecouvet ◽  
Dimitar Boyadzhiev ◽  
Laurence Collette ◽  
Maude Berckmans ◽  
Nicolas Michoux ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1138 ◽  
Author(s):  
Marius E. Mayerhoefer ◽  
Christopher C. Riedl ◽  
Anita Kumar ◽  
Ahmet Dogan ◽  
Peter Gibbs ◽  
...  

Biopsy is the standard for assessment of bone marrow involvement in mantle cell lymphoma (MCL). We investigated whether [18F]FDG-PET radiomic texture features can improve prediction of bone marrow involvement in MCL, compared to standardized uptake values (SUV), and whether combination with laboratory data improves results. Ninety-seven MCL patients were retrospectively included. SUVmax, SUVmean, SUVpeak and 16 co-occurrence matrix texture features were extracted from pelvic bones on [18F]FDG-PET/CT. A multi-layer perceptron neural network was used to compare three combinations for prediction of bone marrow involvement—the SUVs, a radiomic signature based on SUVs and texture features, and the radiomic signature combined with laboratory parameters. This step was repeated using two cut-off values for relative bone marrow involvement: REL > 5% (>5% of red/cellular bone marrow); and REL > 10%. Biopsy demonstrated bone marrow involvement in 67/97 patients (69.1%). SUVs, the radiomic signature, and the radiomic signature with laboratory data showed AUCs of up to 0.66, 0.73, and 0.81 for involved vs. uninvolved bone marrow; 0.68, 0.84, and 0.84 for REL ≤ 5% vs. REL > 5%; and 0.69, 0.85, and 0.87 for REL ≤ 10% vs. REL > 10%. In conclusion, [18F]FDG-PET texture features improve SUV-based prediction of bone marrow involvement in MCL. The results may be further improved by combination with laboratory parameters.


Radiology ◽  
2019 ◽  
Vol 293 (2) ◽  
pp. 451-459 ◽  
Author(s):  
Sarah A. Mattonen ◽  
Guido A. Davidzon ◽  
Jalen Benson ◽  
Ann N. C. Leung ◽  
Minal Vasanawala ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Kusai M. Al-Muqbel

Objective. To determine the value of 18F-FDG PET/CT in detection of bone marrow (BM) metastasis in breast cancer which is considered an early stage of bone metastasis. Patients and Methods. Retrospectively, breast cancer patients with bone metastasis were included. BM metastasis was considered if the lesion was PET positive/CT occult while bone metastasis was considered if the lesion was PET positive/ CT positive. BM metastases were observed sequentially on F18-FDG PET/CT. Results. We included 35 patients. Eighteen patients (51%) had BM metastases in addition to other bone metastases. BM metastases comprised 24% of all lesions. Posttreatment scan was performed on 26/35 patients. Twenty-three percent of BM metastases had resolved completely without causing bone destruction after treatment. Sixty-five percent of BM metastases had converted into bone metastases after treatment. Twelve percent of BM metastases had persisted after treatment. Conclusion. This retrospective study showed clinically by 18F-FDG PET/CT imaging that BM metastasis is an early stage of bone metastasis in breast cancer. Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis. However, more research is needed to study the impact of an early diagnosis of BM metastases on treatment outcome.


Sign in / Sign up

Export Citation Format

Share Document